Fresh off a failed trial that sent its shares plummeting, Novo Nordisk said that one of its experimental obesity drugs helped patients lose nearly 20% of their weight after 24 weeks…
Want to stay on top of the science and politics driving biotech today?
Sign up
to get our biotech newsletter in your inbox.
Good morning. I hope everyone on the East Coast is staying warm. Let’s get into the news today.
How low can obesity drug prices go?
Novo Nordisk has decided to cut by as much as half the U.S. list prices of its weight loss and diabetes drugs Wegovy and Ozempic — escalating an ongoing pricing war with its chief rival Eli Lilly.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/02/24/biotech-news-novo-nordisk-triple-g-obesity-results/)
